3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Hematologic Neoplasms
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Sezary Syndrome
1
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Infectious Mononucleosis
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
9
fludarabine phosphate
7
Peripheral Blood Stem Cell Transplantation
7
Cyclophosphamide
7
Whole-Body Irradiation
4
Radiotherapy
4
Bendamustine Hydrochloride
4
Mycophenolic Acid
3
Filgrastim
3
Cytarabine
3
ibrutinib
2
fludarabine
2
duvelisib
2
Tacrolimus
2
Pentostatin
2
Pentetic Acid
2
Methotrexate
2
Melphalan
2
Lenalidomide
2
Etoposide
2
Dexamethasone
2
Cyclosporine
2
Cord Blood Stem Cell Transplantation
2
Carmustine
2
umbralisib
1
ublituximab
1
tetulomab tetraxetan lu-177
1
sargramostim
1
romidepsin
1
parsaclisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, B-Cell, Marginal Zone
×
Brentuximab Vedotin
×
Clear all
NCT02623920
2017-05-19
S-BR
University of Arizona
Phase 2
Withdrawn